Not recruiting

Study on Sotorasib for Patients with Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer and Comorbidities

Verified siteRegistered drugNo placebo

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of lung cancer known as KRAS G12C-mutated non-small cell lung cancer. This is a specific form of lung cancer that has a particular genetic mutation called KRAS G12C. The trial is testing a medication called sotorasib, which is taken as a film-coated tablet. Sotorasib is an enzyme inhibitor, meaning it works by blocking certain proteins that help cancer cells grow.

The purpose of the study is to see how effective sotorasib is in reducing the size of tumors in patients with this type of lung cancer. Participants in the study will receive sotorasib and will be monitored over time to observe changes in their tumor size and overall health. The study will also look at how long patients can live without their disease getting worse and how long they respond to the treatment. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects of sotorasib.

Throughout the study, various health assessments will be conducted to ensure the safety and well-being of the participants. These assessments will include monitoring for any side effects, changes in vital signs, and laboratory tests. The study aims to gather information on how sotorasib affects patients with different health conditions and how it interacts with other treatments they may have received. The trial is expected to continue until 2028, providing valuable insights into the treatment of KRAS G12C-mutated non-small cell lung cancer.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Initial assessment
Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes a review of medical history and a physical examination.
Laboratory tests are performed to ensure adequate bone marrow and organ function. These tests include blood counts and liver function tests.
A biopsy may be required to confirm the presence of the KRAS G12C mutation in the lung cancer tissue.
Step 2
Treatment initiation
The treatment involves taking sotorasib orally. The dosage and frequency are determined by the study protocol.
The main objective is to evaluate the effectiveness of sotorasib in reducing tumor size.
Step 3
Monitoring and follow-up
Regular follow-up visits are scheduled to monitor the response to treatment. This includes imaging tests to measure tumor size and assess any changes.
Blood tests are conducted to monitor for any side effects and to evaluate overall health.
Step 4
Evaluation of response
The primary endpoint is the Objective Response Rate (ORR), which measures the percentage of patients whose tumors shrink or disappear after treatment.
Secondary endpoints include progression-free survival, duration of response, and overall survival.
Step 5
Completion of study
The study is estimated to end by June 2028. At the end of the study, a final assessment is conducted to evaluate the overall effectiveness and safety of the treatment.
Participants may be asked to provide feedback on their experience and any changes in symptoms or quality of life.

Who can join the trial?

11 criteria

Provide a signed and dated written consent form to participate.
Have a mean resting corrected QT interval (QTc) of less than 470 milliseconds for females or less than 450 milliseconds for males. This is a measure of heart rhythm.
Have enough healthy bone marrow or organ function, shown by specific blood test results.
Be over 18 years old.
Have a confirmed diagnosis of non-small cell lung cancer (NSCLC) at stage III or IV, which cannot be treated with the aim of curing it. If you had treatment for non-metastatic disease before, a new biopsy is needed unless a recent one is available.
Have a documented **KRAS G12C mutation** in the cancer tissue, confirmed by a reliable method.
Have received at least one previous treatment for NSCLC stage III or IV that did not work or the disease came back. This treatment must have included a checkpoint inhibitor, unless there is a medical reason not to use it.
Have an **ECOG status** of 0 to 2, which is a scale to measure daily living abilities, and a life expectancy of at least 12 weeks.
Have at least one tumor that has not been treated with radiation and can be measured accurately at the start of the study. Brain tumors are not considered measurable.
Females must use effective birth control, not be breastfeeding, and have a negative pregnancy test if they can have children. If they cannot have children, they must meet certain criteria, such as being post-menopausal or having had certain surgeries.
Male participants must agree to use barrier contraception, like condoms.

Who cannot join the trial?

4 criteria

Patients who do not have **KRAS G12C-mutated non-small cell lung cancer** cannot participate. This is a specific type of lung cancer with a particular genetic change.
Patients who are not within the specified age range cannot participate. The age range includes adults and older adults.
Both **male** and **female** patients are eligible, so gender is not a reason for exclusion.
Patients who are considered part of a **vulnerable population** are not excluded. This means that groups who might need special protection are not automatically excluded.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Akershus University Hospital
Verified
Lorenskog, Norway
Helse Bergen HF
Verified
Bergen, Norway
Helse Fonna HF
Verified
Haugesund, Norway

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Sotorasib is a medication being studied for its ability to reduce tumor size in patients with advanced non-small cell lung cancer that has a specific mutation known as KRAS G12C. This medication is designed to target and inhibit the activity of the mutated KRAS protein, which is involved in the growth and survival of cancer cells. By blocking this protein, sotorasib aims to slow down or stop the progression of the cancer.

Sotorasib

What is already known about the treatment

Sotorasib – Sotorasib is administered orally in the form of tablets. It is currently being studied in clinical trials for its effectiveness in treating advanced KRAS G12C-mutated non-small cell lung cancer, particularly in patients with additional health conditions. The main therapeutic indication for sotorasib is to reduce tumor size in this specific type of lung cancer. At the molecular level, sotorasib works by selectively inhibiting the KRAS G12C protein, which is involved in the growth and survival of cancer cells. It is classified pharmacologically as a targeted cancer therapy.

Investigated diseases

KRAS G12C-mutated non-small cell lung cancer – This is a type of lung cancer characterized by a specific genetic mutation in the KRAS gene, known as G12C. It primarily affects the cells lining the lungs and is a subtype of non-small cell lung cancer, which is the most common form of lung cancer. The disease progresses as the mutated cells grow uncontrollably, forming tumors that can spread to other parts of the body. This mutation-driven cancer can lead to symptoms such as persistent cough, chest pain, and difficulty breathing as the tumors grow and affect lung function. The progression of the disease can vary, with some patients experiencing rapid growth of tumors, while others may have a slower progression. Understanding the specific mutation helps in targeting treatments that can potentially slow down or reduce tumor growth.